Table of Content

1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Emphasis on Preventing Misdiagnoses of Cardiac Conditions
4.2.2 Rise in Prevalence of Coronary Heart Diseases, Strokes, and Others
4.3 Market Restraints
4.3.1 Stringent Regulations Associated with Product Approval and High Cost of Instruments
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Type of Analyzers
5.1.1 Immuno-Fluorescence Analyzers (IFA)
5.1.2 Radioimmunoassay (RIA) Analyzers
5.1.3 Enzyme Immunoassay (EIA) Analyzers
5.1.4 Other Type of Analyzers
5.2 By End Users
5.2.1 Hospitals
5.2.2 Diagnostic Centers
5.2.3 Academic and Research institutes
5.3 Geography
5.3.1 North America
5.3.1.1 United states
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 F. Hoffmann-La Roche Ltd
6.1.2 Quidel Corporation
6.1.3 CardioGenics Holdings Inc.
6.1.4 Abbott Laboratories
6.1.5 PHC Holdings Corporation (LSI Medience Corporation)
6.1.6 Thermo Fisher Scientific (Fisher Scientific)
6.1.7 Siemens Healthineers AG
6.1.8 Danaher (Beckman Coulter Inc.)
6.1.9 Trinity Biotech PLC
6.1.10 Boditech Med Inc.
6.1.11 Agappe Diagnostics Ltd
6.1.12 Hangzhou Laihe Biotech Co. Ltd


7 MARKET OPPORTUNITIES AND FUTURE TRENDS